Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
October 13, 2022 16:01 ET
|
Invivyd
WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today...
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
October 12, 2022 16:01 ET
|
Invivyd
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity...
Adagio Therapeutics Announces Corporate Name Change to Invivyd
September 12, 2022 07:00 ET
|
Adagio Therapeutics, Inc.
New name reflects Company focus on leveraging its integrated discovery platform to generate anti-viral antibodies that transcend the limits of naturally occurring immunityThe Invivyd corporate mission...
Adagio Therapeutics to Participate in Upcoming Investor Conferences
September 06, 2022 16:01 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 15, 2022 06:30 ET
|
Adagio Therapeutics, Inc.
$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New Candidates for COVID-19 Prevention and...
Adagio Announces David Hering Named Permanent Chief Executive Officer and Director
July 05, 2022 07:26 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors
July 01, 2022 06:30 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics Reports First Quarter 2022 Financial Results
May 13, 2022 06:30 ET
|
Adagio Therapeutics, Inc.
$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024 Additional Data from Adintrevimab Phase 2/3 STAMP Treatment Trial to be...
Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request
April 14, 2022 07:45 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics 宣佈 ADG20（adintrevimab）是第一個滿足主要終點的單克隆抗體，在接觸 2019 冠狀病毒病前後的預防和治療中具有統計學意義，並計劃尋求美國緊急使用授權
March 31, 2022 17:01 ET
|
Adagio Therapeutics, Inc.
與安慰劑相比，在接觸前預防出現 2019 冠狀病毒病症狀的風險降低了 71%，在接觸後預防中降低了 75% 在主要療效分析人群中，與安慰劑相比，患有輕度至中度 2019 冠狀病毒病的參與者的住院或死亡風險降低了 66%，在症狀出現三天內接受治療的參與者中，與安慰劑相比降低了 77% 報告 2021 年全年和第四季度的財務業績；5.91 億美元的現金和投資預計足以為 2024...